Efficacy of TACE in TIPS patients: Comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt

CardioVascular and Interventional Radiology

Volumn 36, Issue 5, 2013, Pages 1336-1343

  Kuo, Yuo Chen ^a   Kohi, Maureen P ^a   Naeger, David M ^a   Tong, Ricky T ^a   Kolli, K Pallav ^a   Taylor, Andrew G ^a   Laberge, Jeanne M ^a   Kerlan, Robert K ^a   Fidelman, Nicholas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hepatocellular carcinoma; Interventional oncology; Transarterial chemoembolization; Transjugular intrahepatic portosystemic shunt

Indexed keywords

CISPLATIN; DOXORUBICIN; ETHIODIZED OIL; IOHEXOL; MITOMYCIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT RESPONSE;

AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84884675047     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-013-0698-8     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90
2. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020-1022
3. El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134(6):1752-1763
4. Llovet JM, Fuster J, Bruix J (2004) The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 10(2 Suppl 1):S115-S120
5. Bouchard-Fortier A, Lapointe R, Perreault P, Bouchard L, Pomier-Layrargues G (2011) Transcatheter arterial chemoembolization of hepatocellular carcinoma as a bridge to liver transplantation: a retrospective study. Int J Hepatol 2011:974514
6. Graziadei IW, Sandmueller H, Waldenberger P et al (2003) Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 9(6):557-563
7. Hayashi PH, Ludkowski M, Forman LM et al (2004) Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. Am J Transplant 4(5):782-787
8. Brown DB, Nikolic B, Covey AM et al (2012) Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 23(3):287-294
9. Haskal ZJ, Martin L, Cardella JF et al (2003) Quality improvement guidelines for transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 14(9 Pt 2):S265-S270
10. Kim MY, Baik SK, Yea CJ et al (2009) Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis. Eur J Gastroenterol Hepatol 21(11):1241-1246
11. Ripoll C, Groszmann RJ, Garcia-Tsao G et al (2009) Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 50(5):923-928
12. Breedis C, Young G (1954) The blood supply of neoplasms in the liver. Am J Pathol 30(5):969-977
13. Kang JW, Kim JH, Ko GY, Gwon DI, Yoon HK, Sung KB (2012) Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt. Acta Radiol 53(5):545-550
14. Kohi MP, Fidelman N, Naeger DM, Laberge JM, Gordon RL, Kerlan RK Jr (2013) Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong? J Vasc Interv Radiol 24(1):68-73
15. Tesdal IK, Wikstrom M, Flechtenmacher C, Filser T, Dueber C (2006) Percutaneous treatment of hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. Cardiovasc Intervent Radiol 29(5):778-784
16. Itkin M, Trerotola SO, Stavropoulos SW et al (2006) Portal flow and arterioportal shunting after transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol 17(1):55-62
17. Clark TW (2008) Stepwise placement of a transjugular intrahepatic portosystemic shunt endograft. Tech Vasc Interv Radiol 11(4):208-211
18. Feldstein VA, Patel MD, LaBerge JM (1996) Transjugular intrahepatic portosystemic shunts: accuracy of Doppler US in determination of patency and detection of stenoses. Radiology 201(1):141-147
19. Haskal ZJ, Carroll JW, Jacobs JE et al (1997) Sonography of transjugular intrahepatic portosystemic shunts: detection of elevated portosystemic gradients and loss of shunt function. J Vasc Interv Radiol 8(4):549-556
20. O'Neil BH, Venook AP (2007) Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. Oncologist 12(12):1425-1432
21. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19(3):329-338
22. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52-60
23. Nonami T, Harada A, Kurokawa T, Nakao A, Takagi H (1997) Hepatic resection for hepatocellular carcinoma. Am J Surg 173(4):288-291
24. Kwan SW, Fidelman N, Ma E, Kerlan RK Jr, Yao FY (2012) Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl 18(6):727-736
25. Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734-1739
26. Kothary N, Weintraub JL, Susman J, Rundback JH (2007) Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol 18(12):1517-1526
27. Georgiades CS, Hong K, D'Angelo M, Geschwind JF (2005) Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 16(12):1653-1659
28. Liapi E, Geschwind JF (2011) Transcatheter arterial chemoembolization for liver cancer: Is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol 34(1):37-49
29. Kudo M, Hatanaka K, Inoue T, Maekawa K (2010) Depiction of portal supply in early hepatocellular carcinoma and dysplastic nodule: value of pure arterial ultrasound imaging in hepatocellular carcinoma. Oncology 78(Suppl 1):60-67
30. Ezzat WR, Lautt WW (1987) Hepatic arterial pressure flow autoregulation is adenosine mediated. Am J Physiol 252(4 Pt 2):H836-HJ845
31. Okuda K, Musha H, Yamasaki T et al (1977) Angiographic demonstration of intrahepatic arterio-portal anastomoses in hepatocellular carcinoma. Radiology 122(1):53-58
32. Ngan H, Peh WC (1997) Arteriovenous shunting in hepatocellular carcinoma: its prevalence and clinical significance. Clin Radiol 52(1):36-40
33. Vogl TJ, Nour-Eldin NE, Emad-Eldin S et al (2011) Portal vein thrombosis and arterioportal shunts: effects on tumor response after chemoembolization of hepatocellular carcinoma. World J Gastroenterol 17(10):1267-1275
34. Kim BK, Kim KA, Park JY et al (2013) Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. Eur J Cancer 49(4):826-834
35. Sato Y, Watanabe H, Sone M et al (2013) Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci 118(1):16-22
36. Hu HT, Kim JH, Lee LS et al (2011) Chemoembolization for hepatocellular carcinoma: Multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort. J Vasc Interv Radiol 22(7):917-923
37. Bargellini I, Bozzi E, Campani D et al (2013) Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol 82(5):e212-e218 Bioengineering